CU20180149A7 - Complejos radio-farmacéuticos - Google Patents

Complejos radio-farmacéuticos

Info

Publication number
CU20180149A7
CU20180149A7 CU2018000149A CU20180149A CU20180149A7 CU 20180149 A7 CU20180149 A7 CU 20180149A7 CU 2018000149 A CU2018000149 A CU 2018000149A CU 20180149 A CU20180149 A CU 20180149A CU 20180149 A7 CU20180149 A7 CU 20180149A7
Authority
CU
Cuba
Prior art keywords
directed
tissue
chelator
radio
residue
Prior art date
Application number
CU2018000149A
Other languages
English (en)
Inventor
Alan Cuthbertson
Dr Stefanie Hammer
Jenny Karlsson
Dr Mark Trautwein
Dr Ernst Weber
Original Assignee
Bayer As
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As, Bayer Pharma AG filed Critical Bayer As
Publication of CU20180149A7 publication Critical patent/CU20180149A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La invención proporciona un método para Ia formación de un complejo de torio que se dirige al tejido,<br /> comprendiendo dicho método;<br /> a) formar un quelante octadentado que comprende cuatro restos hidroxipiridinona (HOPO), sustituidos en Ia posición N con un grupo metilo, y un resto de acoplamiento que termina en un grupo ácido carboxílico;<br /> b) acoplar dicho quelante octadentado a por lo menos un resto que se dirige al tejido que se dirige a prolil endopeptidasa FAP; y<br /> c) contactar dicho agente quelante que se dirige al tejido con una solución acuosa que comprende un ion de por lo menos un isótopo de torio emisor de radiaciones alfa.<br /> </p>
CU2018000149A 2016-06-10 2017-06-06 Complejos radio-farmacéuticos CU20180149A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16173874 2016-06-10
PCT/EP2017/063689 WO2017211809A1 (en) 2016-06-10 2017-06-06 Radio-pharmaceutical complexes

Publications (1)

Publication Number Publication Date
CU20180149A7 true CU20180149A7 (es) 2019-07-04

Family

ID=56132786

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000149A CU20180149A7 (es) 2016-06-10 2017-06-06 Complejos radio-farmacéuticos

Country Status (27)

Country Link
US (1) US20190298865A1 (es)
EP (1) EP3468619A1 (es)
JP (1) JP2019517547A (es)
KR (1) KR20190016544A (es)
CN (1) CN109689115A (es)
AR (1) AR110466A1 (es)
AU (1) AU2017277463A1 (es)
BR (1) BR112018075554A2 (es)
CA (1) CA3026900A1 (es)
CL (1) CL2018003550A1 (es)
CO (1) CO2018013359A2 (es)
CR (1) CR20180581A (es)
CU (1) CU20180149A7 (es)
DO (1) DOP2018000277A (es)
EA (1) EA201892814A1 (es)
EC (1) ECSP18091468A (es)
IL (1) IL263538A (es)
JO (1) JOP20170139A1 (es)
MA (1) MA45225A (es)
MX (1) MX2018015340A (es)
NI (1) NI201800136A (es)
PE (1) PE20190327A1 (es)
PH (1) PH12018502605A1 (es)
SG (1) SG11201810967VA (es)
TW (1) TW201805025A (es)
UY (1) UY37286A (es)
WO (1) WO2017211809A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
TW202024093A (zh) 2018-09-21 2020-07-01 美商安塔製藥公司 作為抗病毒劑之官能化雜環
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
CN118955620A (zh) 2019-07-08 2024-11-15 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4274835A1 (en) 2021-01-07 2023-11-15 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
JPWO2025058000A1 (es) 2023-09-13 2025-03-20
US20250186630A1 (en) 2023-12-12 2025-06-12 Viewpoint Molecular Targeting, Inc. Fibroblast activation protein targeting peptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4880615A (en) 1988-11-25 1989-11-14 Merck & Co., Inc. Stabilized radiopharmaceutical compositions
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2008063721A2 (en) 2006-08-15 2008-05-29 The Regents Of The University Of California Luminescent macrocyclic lanthanide complexes
WO2011040972A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
JP2013515744A (ja) * 2009-12-24 2013-05-09 ルミフォア，インコーポレイテッド 放射性医薬品錯体
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
NL2009131C2 (en) * 2012-07-05 2014-01-07 Stichting Vu Vumc Compound and use of compound to prepare a radiollabelled compound.
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques

Also Published As

Publication number Publication date
JP2019517547A (ja) 2019-06-24
EP3468619A1 (en) 2019-04-17
KR20190016544A (ko) 2019-02-18
EA201892814A1 (ru) 2019-06-28
CR20180581A (es) 2019-02-11
CA3026900A1 (en) 2017-12-14
JOP20170139A1 (ar) 2017-12-10
NI201800136A (es) 2019-04-29
CO2018013359A2 (es) 2018-12-14
UY37286A (es) 2018-01-31
PE20190327A1 (es) 2019-03-05
AR110466A1 (es) 2019-04-03
MA45225A (fr) 2019-04-17
PH12018502605A1 (en) 2019-10-21
AU2017277463A1 (en) 2019-01-03
WO2017211809A1 (en) 2017-12-14
SG11201810967VA (en) 2019-01-30
DOP2018000277A (es) 2018-12-31
CN109689115A (zh) 2019-04-26
ECSP18091468A (es) 2018-12-31
US20190298865A1 (en) 2019-10-03
CL2018003550A1 (es) 2019-02-01
BR112018075554A2 (pt) 2019-10-01
TW201805025A (zh) 2018-02-16
MX2018015340A (es) 2019-03-28
IL263538A (en) 2019-01-31

Similar Documents

Publication Publication Date Title
CO2018013359A2 (es) Complejos radio-farmacéuticos
CR20170256A (es) Complejos radiofarmacéuticos
CL2019001213A1 (es) Procedimiento para la recuperación de litio.
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
AR107957A1 (es) Complejos radiofarmacéuticos de torio
AR097069A1 (es) Fluidos de tratamiento que contienen un agente quelante perfluorado y métodos para su uso
MX388400B (es) Una composición de dos componentes, que comprende ácido acetilsalicílico.
AR103530A1 (es) Métodos y sistemas que emplean un ácido iminodiacético sulfonado durante operaciones de tratamiento subterráneas
PL418162A1 (pl) Niskotemperaturowy rozkład heksacyjanożelazianów metali przejściowych
CL2018001656A1 (es) Procedimiento para la preparación de un agente quelante
RU2013152578A (ru) Способ химической очистки и дезактивации контуров исследовательских и энергетических реакторов, охлаждаемых водой под давлением
CO6700878A2 (es) Composición dentífrica con astringencia reducida
RU2015132792A (ru) Способ получения магнитоактивного соединения
AR103797A1 (es) Composición disolvente líquida, método para su preparación y su aplicación en la eliminación de sulfuros metálicos
ES229745A1 (es) UN PROCEDIMIENTO PARA LA DEFORMACIoN PERMANENTE DEL CABELLO, TANTO PARA ONDULARLO COMO PARA DESENCRESPARLO